FindTrial
Sign In

Translational Medicine Study of MiniPDX Susceptibility Testing in Individualized Treatment of Solid Tumor Patients

Translational Medicine Study of MiniPDX Susceptibility Testing in Individualized Treatment of Solid Tumor Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038602
Enrollment
Unknown
Registered
2020-09-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid tumor

Interventions

case series: PDX model establishment and MiniPDX drug sensitivity test

Sponsors

Suzhou Canglang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Pathological histological diagnosis of advanced gastric cancer, lung cancer and other malignant tumors; 2. The patients could provide biopsy,fresh tumor tissue or pleuroperitoneal fluids samples; 3. Objective tumors that meet RECIST 1.1 criteria and can be evaluated by CT/MRI; 4. KPS score = 60, expected survival time = 3 months; 5. The patient voluntarily signed the informed consent form, with good compliance.

Exclusion criteria

Exclusion criteria: 1. Patients with incomplete clinical data; 2. Those who have not undergone surgery or have unplanned reoperation after surgery; 3. The patient was found to have a second tumor during the treatment and interfered with the study.

Design outcomes

Primary

MeasureTime frame
ORR;—

Secondary

MeasureTime frame
PFS;OS;—

Countries

china

Contacts

Public ContactYu Qian

Suzhou Canglang Hospital

services@lidebiotech.com13962108612

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026